Clinical Trial Detail

NCT ID NCT02826161
Title A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in Patients With Advanced, Previously Treated, Non-Squamous Non-Small Cell Lung Cancer (CanStem43L)
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

lung non-small cell carcinoma

Therapies

Napabucasin + Paclitaxel

Paclitaxel

Age Groups: adult senior

No variant requirements are available.